03:46 PM EST - Aeterna Zentaris Inc. : announced that Jacek Pinski, MD, PhD, Associate Professor of Medicine at the Norris Comprehensive Cancer Center of the University of Southern California, will present updated interim results from a Phase 1 clinical trial in prostate cancer with AEZS-108 (zoptarelin doxorubicin), the Company's targeted cytotoxic luteinizing hormone releasing hormone analog. The presentation will take place on Thursday, February 2, during the American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco. Aeterna Zentaris Inc.
shares T.AEZ are trading up $0.04 at $1.62.
